MedPath
NMPA Approval

Rituximab Injection

国药准字S20200022

September 30, 2020

Drug Information

利妥昔单抗注射液

达伯华

达伯华

注射剂

100mg(10ml)/瓶

生物制品

September 30, 2020

Company Information

Applicant Company

苏州工业园区东平街168号

Manufacturing Company

苏州工业园区东平街168号

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

利妥昔单抗注射液 - NMPA 批准文号 | MedPath